Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

Figure 3

Microvessel density (MVD) as CD31 positive profiles in SW480 and WM239 subcutaneous xenografts; Mean (SEM) are plotted. There were significant reductions in MVD in both SW480 (A) and WM239 (B) xenografts between CTX and control groups (*p < 0.05). Western blotting of tumor lysates for TSP-1 revealed significant increases in TSP-1 levels in CTX treated SW480 tumors compared to control (C; *p < 0.05), but significant decreases in CTX treated WM239 tumors compared to control (D; *p < 0.05).

Back to article page